Clearside Biomedical Secures Nasdaq Listing Compliance
Published on 10/10/2025 at 08:00 | Redaktion boerse-global.de
Clearside Biomedical has successfully navigated the threat of delisting from the Nasdaq exchange, marking a critical milestone for the biotechnology firm. The company confirmed it has regained compliance with the exchange’s minimum bid price requirement, resolving a significant challenge that had clouded its financial standing.
The path to compliance culminated with a decisive corporate action—a 1:15 reverse stock split that effectively elevated the share price above the critical $1 threshold. This technical adjustment came after an extended period of non-compliance that began with an initial notification from Nasdaq in February. Despite receiving an extension to meet requirements, the company’s stock failed to sustain the necessary trading levels, leading to a formal delisting warning in August.
Market Response... Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
